DIN 02559773 — ANDEMBRY 200 MG
ANDEMBRY is a solution of Garadacimab marketed by CSL BEHRING CANADA INC. The full Garadacimab monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.
- DIN
- 02559773
- Brand name
- ANDEMBRY
- Active ingredient
- Garadacimab
- Strength
- 200 MG
- Dosage form
- SOLUTION
- Route
- SUBCUTANEOUS
- Manufacturer
- CSL BEHRING CANADA INC
- Health Canada status
- MARKETED
- Drug class
- Monoclonal antibody inhibitor of activated Factor XII (FXIIa)
Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.